Reuters logo
BRIEF-Catalyst biosciences, CMC Biologics announce manufacturing agreement
May 24, 2016 / 12:51 PM / a year ago

BRIEF-Catalyst biosciences, CMC Biologics announce manufacturing agreement

May 24 (Reuters) - Catalyst Biosciences Inc

* Catalyst Biosciences and CMC Biologics announce manufacturing agreement for Catalyst’s next-generation factor VIIA product CB 813D

* Catalyst plans to initiate clinical pivotal trial in hemophilia A and B “inhibitor” patients in 2017

* Catalyst Biosciences Inc says remain on track to initiate Phase 2/3 clinical pivotal trial of CB 813D, advanced hemophilia product candidate, in 2017

* “companies committed to establishing manufacturing capabilities for next-generation factor VIIA CB 813D” Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below